Mercury Bio Partners with Meta-Flux to Accelerate CNS Therapeutics Using AI-Powered Disease Modeling and Novel Delivery Platform
核心洞察
Mercury Bio (搜索) and Meta-Flux (搜索) announced a strategic collaboration to advance large-molecule therapeutics for Parkinson's and Alzheimer's diseases using combined AI modeling and delivery technologies.
The partnership integrates Mercury Bio (搜索)'s yEV™ (搜索) platform, which delivers therapeutic proteins and RNA into neurons (搜索) across the blood-brain barrier (搜索), with Meta-Flux (搜索)'s computational disease modeling capabilities.
Mercury Bio (搜索) recently demonstrated successful protein delivery into neurons (搜索) across the blood-brain barrier (搜索) in murine models, suggesting potential for treating neurological disorders (搜索).
Mercury Bio (搜索), a biotechnology company developing large-molecule therapeutics for neurodegenerative diseases, has entered into a strategic collaboration with AI-powered disease simulation company Meta-Flux (搜索) to accelerate development of central nervous system (CNS) therapeutics for Parkinson's and Alzheimer's diseases.
The partnership combines Mercury Bio (搜索)'s patented yeast extracellular vesicle (yEV™ (搜索)) technology with Meta-Flux (搜索)'s disease-scale computational modeling platform to strengthen therapeutic pipeline development through improved target selection, pathway prioritization, and early development decision-making for diseases driven by intracellular pathology.
Novel Delivery Platform Addresses Key CNS Challenges
Mercury Bio (搜索)'s yEV™ (搜索) technology is designed to deliver therapeutic proteins, RNA, and other large-molecule biologics into neurons (搜索), release them into the cytoplasm, and avoid endosomal degradation, including across the blood-brain barrier (搜索). The company recently shared pre-clinical research results demonstrating successful delivery of proteins, in the form of nanobodies, into neurons across the blood-brain barrier in murine models.
"Therapeutic progress in Parkinson's and Alzheimer's diseases has been constrained by four fundamental challenges: crossing the blood–brain barrier, entering the neuron, releasing the drug into the cytoplasm while avoiding endosomal degradation, and targeting the intracellular pathways (搜索) that drive disease," said Bruce McCormick, Chief Executive Officer of Mercury Bio (搜索). "Our focus at Mercury Bio is on advancing therapeutics that address those intracellular mechanisms. The yEV technology supports that goal, and Meta-Flux (搜索) adds the biological intelligence needed to ensure we are targeting the right pathways with confidence."
AI-Powered Disease Modeling Integration
Meta-Flux (搜索)'s platform integrates multi-omics data and systems-biology approaches to map pathway dynamics and cellular state changes in neurodegenerative disease (搜索), including their response to yEV-mediated delivery. The disease-scale simulations model how neuronal pathways respond to therapeutic intervention, enabling more informed program design and biomarker strategies.
"This partnership allows us to evaluate disease mechanisms and therapeutic hypotheses in a context that has historically been inaccessible," said Lee Sherlock, Chief Executive Officer of Meta-Flux (搜索). "By applying our modeling framework to Mercury Bio (搜索)'s CNS programs, we can help strengthen the biological rationale behind advancing large-molecule therapeutics for neurodegenerative disease (搜索)."
Strategic Leadership Expansion
The collaboration announcement follows Mercury Bio (搜索)'s recent appointment of Cassandra "Casey" Perkins as Vice President of Corporate Strategy & Business Development. Perkins brings over 25 years of leadership in biotech and pharmaceuticals, with experience in commercialization of transformational advanced therapies including ZOLGENSMA® (搜索), and expertise across rare and orphan diseases, as well as cell and gene therapies in neurology, oncology, and immunology.
Perkins will lead corporate strategy and business development, focusing on strategic partnerships and investor relations as the company accelerates development of its intracellular yEV™ (搜索) delivery platform. The drug delivery platform utilizes yeast-derived exosomes, a type of extracellular vesicle, to enable transmission of proteins, RNA, and other molecular therapeutics between cells.
Platform Technology and Applications
Mercury Bio (搜索)'s biomolecular drug delivery platform employs cell-specific targeting with a novel system for drug encapsulation in biological vesicles. The technology prioritizes safety and efficacy while reducing side effects, resulting in an advanced drug delivery system in a scalable, low-cost production platform designed to unlock the potential of protein therapeutics, RNA therapeutics, and small-molecule drugs.
The collaboration reflects a shared commitment to building a more disciplined, data-driven approach to advancing therapeutics for diseases of the brain, particularly in areas where conventional therapies have largely been limited to symptomatic treatment for diseases driven by intracellular pathology.